tetano
Editor, Senior Moderator
Gastroenterology
. 2020 Sep 24;S0016-5085(20)35210-0.
doi: 10.1053/j.gastro.2020.09.029. Online ahead of print.
Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease
Mayte Su?rez-Fari?as[SUP] 1 [/SUP], Minami Tokuyama[SUP] 2 [/SUP], Gabrielle Wei[SUP] 3 [/SUP], Ruiqi Huang[SUP] 1 [/SUP], Alexandra Livanos[SUP] 2 [/SUP], Divya Jha[SUP] 2 [/SUP], Anais Levescot[SUP] 4 [/SUP], Haritz Irizar[SUP] 5 [/SUP], Roman Kosoy[SUP] 3 [/SUP], Sascha Cording[SUP] 4 [/SUP], Wenhui Wang[SUP] 3 [/SUP], Bojan Losic[SUP] 3 [/SUP], Ryan Ungaro[SUP] 6 [/SUP], Antonio Di'Narzo[SUP] 3 [/SUP], Gustavo Martinez-Delgado[SUP] 2 [/SUP], Maria Suprun[SUP] 7 [/SUP], Michael J Corley[SUP] 8 [/SUP], Aleksandar Stojmirovic[SUP] 9 [/SUP], Sander M Houten[SUP] 3 [/SUP], Lauren Peters[SUP] 3 [/SUP], Mark Curran[SUP] 9 [/SUP], Carrie Brodmerkel[SUP] 9 [/SUP], Jacqueline Perrigoue[SUP] 9 [/SUP], Joshua R Friedman[SUP] 9 [/SUP], Ke Hao[SUP] 3 [/SUP], Eric E Schadt[SUP] 3 [/SUP], Jun Zhu[SUP] 3 [/SUP], Huaibin M Ko[SUP] 10 [/SUP], Judy Cho[SUP] 11 [/SUP], Marla C Dubinsky[SUP] 6 [/SUP], Bruce E Sands[SUP] 6 [/SUP], Lishomwa Ndhlovu[SUP] 8 [/SUP], Nadine Cerf-Bensusan[SUP] 12 [/SUP], Andrew Kasarskis[SUP] 3 [/SUP], Jean Frederic Colombel[SUP] 6 [/SUP], Noam Harpaz[SUP] 10 [/SUP], Carmen Argmann[SUP] 13 [/SUP], Saurabh Mehandru[SUP] 14 [/SUP]
Affiliations
Abstract
Background and aims: The presence of gastrointestinal symptoms and high levels of viral RNA in the stool suggest active Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) replication within enterocytes.
Methods: Here, in multiple, large cohorts of patients with inflammatory bowel disease (IBD), we have studied the intersections between Coronavirus Disease 2019 (COVID-19), intestinal inflammation and IBD treatment.
Results: A striking expression of ACE2 on the small bowel enterocyte brush border supports intestinal infectivity by SARS-CoV-2. Commonly used IBD medications, both biologic and non-biologic, do not significantly impact ACE2 and TMPRSS2 receptor expression in the uninflamed intestines. Additionally, we have defined molecular responses to COVID-19 infection that are also enriched in IBD, pointing to shared molecular networks between COVID-19 and IBD.
Conclusions: These data generate a novel appreciation of the confluence of COVID-19- and IBD-associated inflammation and provide mechanistic insights supporting further investigation of specific IBD drugs in the treatment of COVID-19.
Keywords: COVID-19; GI tract; IBD medications; network analyses.
. 2020 Sep 24;S0016-5085(20)35210-0.
doi: 10.1053/j.gastro.2020.09.029. Online ahead of print.
Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease
Mayte Su?rez-Fari?as[SUP] 1 [/SUP], Minami Tokuyama[SUP] 2 [/SUP], Gabrielle Wei[SUP] 3 [/SUP], Ruiqi Huang[SUP] 1 [/SUP], Alexandra Livanos[SUP] 2 [/SUP], Divya Jha[SUP] 2 [/SUP], Anais Levescot[SUP] 4 [/SUP], Haritz Irizar[SUP] 5 [/SUP], Roman Kosoy[SUP] 3 [/SUP], Sascha Cording[SUP] 4 [/SUP], Wenhui Wang[SUP] 3 [/SUP], Bojan Losic[SUP] 3 [/SUP], Ryan Ungaro[SUP] 6 [/SUP], Antonio Di'Narzo[SUP] 3 [/SUP], Gustavo Martinez-Delgado[SUP] 2 [/SUP], Maria Suprun[SUP] 7 [/SUP], Michael J Corley[SUP] 8 [/SUP], Aleksandar Stojmirovic[SUP] 9 [/SUP], Sander M Houten[SUP] 3 [/SUP], Lauren Peters[SUP] 3 [/SUP], Mark Curran[SUP] 9 [/SUP], Carrie Brodmerkel[SUP] 9 [/SUP], Jacqueline Perrigoue[SUP] 9 [/SUP], Joshua R Friedman[SUP] 9 [/SUP], Ke Hao[SUP] 3 [/SUP], Eric E Schadt[SUP] 3 [/SUP], Jun Zhu[SUP] 3 [/SUP], Huaibin M Ko[SUP] 10 [/SUP], Judy Cho[SUP] 11 [/SUP], Marla C Dubinsky[SUP] 6 [/SUP], Bruce E Sands[SUP] 6 [/SUP], Lishomwa Ndhlovu[SUP] 8 [/SUP], Nadine Cerf-Bensusan[SUP] 12 [/SUP], Andrew Kasarskis[SUP] 3 [/SUP], Jean Frederic Colombel[SUP] 6 [/SUP], Noam Harpaz[SUP] 10 [/SUP], Carmen Argmann[SUP] 13 [/SUP], Saurabh Mehandru[SUP] 14 [/SUP]
Affiliations
- PMID: 32980345
- DOI: 10.1053/j.gastro.2020.09.029
Abstract
Background and aims: The presence of gastrointestinal symptoms and high levels of viral RNA in the stool suggest active Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) replication within enterocytes.
Methods: Here, in multiple, large cohorts of patients with inflammatory bowel disease (IBD), we have studied the intersections between Coronavirus Disease 2019 (COVID-19), intestinal inflammation and IBD treatment.
Results: A striking expression of ACE2 on the small bowel enterocyte brush border supports intestinal infectivity by SARS-CoV-2. Commonly used IBD medications, both biologic and non-biologic, do not significantly impact ACE2 and TMPRSS2 receptor expression in the uninflamed intestines. Additionally, we have defined molecular responses to COVID-19 infection that are also enriched in IBD, pointing to shared molecular networks between COVID-19 and IBD.
Conclusions: These data generate a novel appreciation of the confluence of COVID-19- and IBD-associated inflammation and provide mechanistic insights supporting further investigation of specific IBD drugs in the treatment of COVID-19.
Keywords: COVID-19; GI tract; IBD medications; network analyses.